Takeda gains after FY24 guidance raise, CEO transition
Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.
Drugmaker Takeda's CEO Weber to step down, raises profit forecast
Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...
Takeda picks first woman as CEO of centuries-old drugmaker
Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.
Takeda 9-Month EPS Rises, Revises FY24 Outlook, Julie Kim To Be New CEO
Concurrently, the company also announced the decision to appoint Julie Kim as the Chief Executive Officer, succeeding Christophe Weber, who plans to retire from the position in June 2026. Kim ...
FiercePharma4h
Takeda taps Julie Kim to take over for retiring CEO Christophe Weber
Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...
Neurocrine’s Strategic Partnership with Takeda: A Catalyst for Growth and Financial Upside
Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...
The Daily Telegraph17d
There is growth ahead for this pharma company as the takeover dust settles
While Sauerbronn is pleased with the progress Takeda is making in reducing its debts, helped by strong cash flows and a slew of asset sales, margin growth has been slower than he expected.